DrugScience: Launch of the Medical Psychedelics Working Group - 2.00-4.00pm Tuesday 14th July

Drug Science believes that the future of psychedelic medicine is extremely promising, and there is potential for widespread application of psychedelic drugs within public health models.  The UK is a world leader in the development of clinical psychedelic research, which is now expanding globally.

However, current UK regulations have created serious and considerable barriers to legitimate research associated with Schedule 1 regulations. While current legislation does not preclude scientific research with these drugs, it does make them significantly more difficult, time-consuming and costly to study.

With a greater understanding amongst policy makers, academics, the media and the general public, there are realistic prospects of regulatory approval, leading to the evidenced possibility that medical psychedelics can be used safely, feasibly and with the potential for lasting therapeutic benefits.

Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group (MPWG) is a consortium of Drug Science experts, leading academics and researchers, policy specialists and industry partners. The group’s aim is to create a rational and enlightened approach to psychedelic research and clinical treatment. The group will explore innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary and secondary healthcare. Evidence-based science, sharing data, and strong partnerships are keys to success for the psychedelic community.

On the 14th of July, we would like you to join us in celebrating the launch of this group with a series of talks from some of the best and brightest minds in this field. Visit the DrugScience website to book one of the free but limited places.